TME PHARM.CONF.IPO EO 1- Net Asset Momentum
TME PHARM.CONF.IPO EO 1- net asset momentum. TME PHARM.CONF.IPO EO 1- (0N6A) recorded a net asset momentum of -197.8% as of December 2025, with net assets of €-1.58 Million EUR. Net Asset Momentum measures the year-over-year percentage change in net assets (total assets minus total liabilities), indicating how rapidly the company is building or eroding its equity base. Explore 0N6A operating cash to total liabilities to assess how comfortably operating cash covers total debt obligations.
YoY Momentum
Current Net Assets
Years of Data
Country
Net Asset Momentum of TME PHARM.CONF.IPO EO 1- (2021–2025)
Net asset momentum of TME PHARM.CONF.IPO EO 1- from 2021 to 2025. This chart tracks TME PHARM.CONF.IPO EO 1-'s year-over-year net asset growth across 5 annual reporting periods from 2021 to 2025. The most recent momentum reading is -197.8%, with net assets of €-1.58 Million EUR as of December 2025. See 0N6A net assets for net asset value and shareholders' equity analysis.
TME PHARM.CONF.IPO EO 1- Net Asset Momentum by Year (2021–2025)
TME PHARM.CONF.IPO EO 1- net asset momentum by year from 2021 to 2025. The table below shows the complete annual net asset history for TME PHARM.CONF.IPO EO 1- from 2021 to 2025, covering 5 yearly periods. Each row includes total assets, total liabilities, net assets, and the year-over-year momentum figure for that period. For live market cap and overall valuation, see 0N6A market cap.
| Year | Net Assets (EUR) | Total Assets | Total Liabilities | YoY Momentum |
|---|---|---|---|---|
| 2025 | €-1.58 Million | €2.14 Million | €3.72 Million | ▼ -197.8% |
| 2024 | €1.61 Million | €3.41 Million | €1.79 Million | ▲ +649.0% |
| 2023 | €-294.00K | €2.49 Million | €2.79 Million | ▲ +76.9% |
| 2022 | €-1.27 Million | €5.24 Million | €6.51 Million | ▼ -128.3% |
| 2021 | €4.50 Million | €9.77 Million | €5.27 Million | — |